Publications by authors named "E Di Pierro"
Obesity is an established risk factor for breast cancer development and worsened prognosis; however, the mechanisms for this association - and the potential benefits of weight loss - have not been fully explored. The adipose environment surrounding breast tumors, which is inflamed in obesity, has been implicated in tumor progression. An emerging therapeutic target for cancer is TREM2, a transmembrane receptor of the immunoglobulin superfamily that is expressed on macrophages in adipose tissue and tumors.
View Article and Find Full Text PDFArticle Synopsis
- Thalassemias are genetic disorders that affect how our bodies make certain parts of blood called globin chains, and in Iraq, a specific type called β-thalassemia is more common.
- A study from a hospital in Erbil looked at 137 cases of β-thalassemia and 97 cases of α-thalassemia, finding some patients with rare genetic changes that weren’t previously known.
- The researchers used advanced tests to understand these changes better, which showed that thalassemia has different types in that region, highlighting the need for better ways to find and diagnose these rare genetic issues.
Article Synopsis
- - Hepatocellular carcinoma is a major form of liver cancer, accounting for about 80% of liver tumors, and is projected to become increasingly deadly by 2040; however, little is known about its incidence and survival rates in children compared to adults.
- - In a study analyzing data from 2003 to 2020, pediatric hepatocellular carcinoma had a low and stable incidence rate (0.056 per 100,000) while adults had a much higher rate (7.793), with trends showing a decline in adult cases post-2015.
- - Survival rates for pediatric patients (46.4%) were significantly higher than for adults (20.7%), and race/ethnicity played a
Porphyria denotes a heterogeneous group of metabolic disorders caused by anomalies in the biosynthesis of heme, a crucial component of hemoglobin and other vital hemoproteins [...
View Article and Find Full Text PDFBackground: We describe the first case of a pediatric patient with acute intermittent porphyria and severe chronic porphyric neuropathy treated with givosiran, a small-interfering RNA that drastically decreases delta-aminolevulinic acid production and reduces porphyric attacks' recurrence.
Case Report: A 12-year-old male patient with refractory acute intermittent porphyria and severe porphyric neuropathy was followed prospectively for 12 months after givosiran initiation (subcutaneous, 2.5 mg/kg monthly).